Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

446
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
446
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Prodrugs01:30

Prodrugs

2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.6K
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carrots and Sticks: Incentives in Shaping Digital Health Products.

The American journal of bioethics : AJOB·2026
Same author

Two decades of growth and trends in the FDA authorization of digital medical devices.

NPJ digital medicine·2026
Same author

Use and Public Reporting of Predetermined Change Control Plans for AI-Enabled Medical Devices.

JAMA health forum·2026
Same author

BRIDGE pilot study: a bilateral regulatory investigation of data governance and exchange.

NPJ digital medicine·2026
Same author

Case-Based Lessons on Remote Patient Monitoring in Neurology Using Consumer-Grade Wearables.

Journal of central nervous system disease·2026
Same author

FDA-authorized software as a medical device in mental health: a perspective on evidence, device lineage, and regulatory challenges.

Npj mental health research·2025

Related Experiment Video

Updated: Jun 22, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

215

FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time.

Kathleen L Miller1, Ariel D Stern2, Aaron Kearsley3

  • 1Kathleen L. Miller (kathleen.miller@hhs.gov), Department of Health and Human Services, Washington, D.C.

Health Affairs (Project Hope)
|July 1, 2024
PubMed
Summary

The Food and Drug Administration's (FDA) Breakthrough Therapy Designation (BTD) program accelerates drug development. This analysis shows BTD drugs spend 30% less time in late-stage clinical trials, improving patient access to novel therapies.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Related Experiment Videos

Last Updated: Jun 22, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

215
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Area of Science:

  • Regulatory Science
  • Pharmaceutical Development
  • Clinical Trials

Background:

  • The FDA's Breakthrough Therapy Designation (BTD) program aims to expedite patient access to innovative treatments.
  • Efficient clinical development is crucial for delivering safe and effective therapies to patients.

Purpose of the Study:

  • To evaluate the impact of the FDA's BTD program on the duration of late-stage clinical development.
  • To quantify the effect of BTD on the time from end-of-Phase-II meeting to marketing approval.

Main Methods:

  • Analysis of a dataset of key development milestones for drugs approved between 2006 and 2020.
  • Comparison of development timelines for BTD-designated drugs versus a control group of comparator drugs identified by FDA experts.

Main Results:

  • The BTD program was associated with a 30% reduction in the time spent in late-stage clinical development.
  • This indicates a significant acceleration in the drug approval process for BTD-designated therapies.

Conclusions:

  • The FDA's BTD program effectively shortens late-stage clinical development timelines.
  • Findings support regulatory and innovation policies designed to enhance medical product development efficiency and timely patient access.